Bellerophon Therapeutics (BLPH)
(Delayed Data from OTC)
$0.04 USD
0.00 (0.00%)
Updated Sep 12, 2024 10:30 AM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Bellerophon Therapeutics, Inc. [BLPH]
Reports for Purchase
Showing records 1 - 20 ( 37 total )
Company: Bellerophon Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Dropping Coverage Following Phase 3 REBUILD Trial Failure
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Bellerophon Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Phase 3 REBUILD Trial Failure and Shifting INOpulse Focus; PT to $2
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Bellerophon Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Near-Term Platform Catalyst-INOpulse Phase 3 Topline Expected Mid-2023; Reit Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Bellerophon Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Near-Term INOpulse Clarity With REBUILD Readout Mid-2023; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Bellerophon Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Focusing on Phase 3 REBUILD Trial in fILD-Top-Line Expected 3Q23
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Bellerophon Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Phase 3 REBUILD Trial Defines Top 2022 Focus-INOpulse Upside in PH-Sarc
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Bellerophon Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Registrational PH-ILD Trial Outcome Remains the Key Focus in 2022
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Bellerophon Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Bellerophon Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
PH-Sarc Hemodynamic Benefit, With Phase 3 fILD Top-line On Horizon in 2022
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Bellerophon Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
INOpulse Progress Defined by fILD and PH-Sarc; Data Expected YE21
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Bellerophon Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Bellerophon Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Merits of INOpulse Phase 2 PH-Sarc Data Anticipated 2021
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Bellerophon Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
INOpulse Platform Steady As She Goes; Expecting PH-Sarc Data in 2021
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Bellerophon Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Phase 2 Top-line in PH-Sarc Expected 2021 to Build INOpulse Headway
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Bellerophon Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
REBUILD and COViNOX Maintain the Momentum of INOpulse
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Bellerophon Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Model Update and Thoughts Heading Into 3Q20; Reit Buy and $30PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Bellerophon Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Bellerophon Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
INOpulse Program Gains Momentum With IND Approval for COVID-19; Reit Buy and $30 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Bellerophon Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
INOpulse Program Momentum Heading Into PH-PF Phase 3 Trial, and Positive Impact for COVID-19; Reit Buy and $30 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Bellerophon Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Positive Topline INOpulse Data in PH-PF Patients
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A